Dr. Ken Anderson Elected Officer To American Society Of Hematology – Dr. Ken Anderson is one of five newly elected officers to the American Society of Hematology’s (ASH) Executive Committee. Dr. Anderson is a renowned hematologist specializing in the treatment of multiple myeloma. He will begin serving his four-year term in January 2010. For more information, please see the ASH press release.

Revlimid Covered By Australian Government – Revlimid (lenalidomide) is now listed for the treatment of myeloma on the Pharmaceutical Benefits Scheme, a list of drugs subsidized by the Australian government. Revlimid will be subsidized for the next four years at a cost of A$104 million (US$94 million). For more information, please visit the Investor Village Web site.

Potential New Myeloma Treatment Starts Phase 1 Trial Extension For AML – Innate Pharma received approval from the French Regulatory authorities to begin an extension of the Phase 1 trial with IPH 2101 in patients with acute myeloid leukemia (AML). The company recently also started Phase 2 clinical trials with IPH 2101 for multiple myeloma. For more information, please see the Innate Pharma press release (pdf).

MMRF Race For Research – On November 15, the Multiple Myeloma Research Foundation (MMRF) is sponsoring a 5K walk/run. It will be held in Alexandria, VA and will start at 7:30 a.m. The MMRF is looking for participants and sponsors. For more information, please visit the MMRF Web site.

For a more detailed listing of myeloma related events, please check the Myeloma Beacon Events Calendar.